生物銀行市場報告：2031 年趨勢、預測與競爭分析

全球生物銀行市場前景光明，為製藥和生物技術公司、CRO、學術和研究機構以及醫院市場提供了機會。預計到 2031 年，全球生物銀行市場規模將達到 68 億美元，2025 年至 2031 年的複合年成長率為 10.5%。該市場的主要驅動力是對基因檢測和精準醫療日益成長的需求、新生兒臍帶血幹細胞儲存的日益普及以及虛擬生物銀行軟體的出現。

• Lucintel 預測，基於產品或服務，設備將在預測期內實現最高成長。
• 根據應用，再生醫學預計在預測期內仍將是最大的細分市場。
• 根據地區來看，預計亞太地區將在預測期內實現最高成長。

生物銀行市場的策略成長機會

從各種可用應用程式來看，生物銀行市場存在多種成長機會。透過利用這些機會，相關人員可以擴大參與度，並最終影響研究和公共衛生。本概述重點在於生物銀行框架內的成長動態，解釋關鍵的成長模式和不斷擴大的市場地域範圍所定義的廣泛應用前景。

• 基因組學研究：基因庫計劃的趨勢正在增加生物銀行市場對此類設施的需求。生物庫為基因組研究提供了多樣化的群體和大量的樣本。此應用將促進基因多態性、疾病發展和疾病管理治療等領域的研究。生物庫護理有望成為基因組學研究的一部分，有助於發展其他精準和靶向醫療領域。
• 個人化醫療：個人化醫療是生物庫的機會溫床，該領域的發展不容錯過。生物庫現在能夠利用實際的生物檢體和詳細的臨床病史來促進研究，以支持個人化治療和藥物發現。該應用將使患者的疾病診斷更加可靠、治療更有針對性，進一步促進個人化醫療領域的發展。
• 公共衛生研究：生物庫是流行病學研究以及基於健康的研究的重要樣本來源，包括但不限於測量疾病發生、影響疾病發生的因素以及疾病控制和預防的研究。成長機會包括加強生物庫資源，這對於流行病學和公共衛生方法至關重要。這將加強解決公共衛生問題以及製定和實施有效的衛生策略和計劃的能力。
• 藥物開發和臨床試驗：生物庫是藥物開發和臨床研究的核心，因為它們提供滿足所有需求的生物研究材料。參與這些機會意味著與製藥和研究公司合作，滿足他們的藥物開發和臨床研究需求。該應用加速了潛在藥物的發現，同時改善了藥物開發過程。
• 疾病特異性生物庫：疾病特異性生物庫的開發是另一個成長領域，有可能為癌症、心血管疾病、罕見遺傳疾病等建立體質生物庫。此類生物庫對於提高我們對疾病、其生物標記和治療方法的理解很有價值。該應用將促進特定的研究工作，同時也將進一步推動特定疾病的診斷和治療需求。

戰略生物銀行錯失了生物銀行市場出現的機會。基因組學研究、個人化醫療、公共衛生研究、藥物開發和特異性疾病的生物庫代表著機會和影響不斷成長的領域。利用這些機會將推動研究，改善個人醫療保健，並解決關鍵的公共衛生問題。

生物銀行市場促進因素與挑戰

生物銀行市場具有多種市場促進因素和挑戰，包括但不限於技術、監管和經濟。相關人員需要了解市場促進因素和挑戰，以進入市場並利用不斷成長的機會。

推動生物銀行市場發展的因素有：

• 個人化醫療需求不斷增加：近年來，由於對個人化醫療的日益重視，生物銀行市場顯著成長。 「個人化治療」一詞明確地建構了治療的概念，這種治療需要大量的生物和臨床資料。生物庫透過提供廣泛、全面和複雜的樣本收集來研究個人化醫療和改善醫療服務，從而滿足這項要求。
• 納入新的研究舉措領域：研究舉措範圍的擴大，包括基因組學、流行病學和研究與開發，正在增加對生物庫資源的需求。了解此類研究舉措的成長，我們需要更多特異性且易於取得的生物樣本。為了做出有意義的科學貢獻，生物庫正在著手擴大其所持有的生物樣本數量並擴大其範圍以滿足各種研究目的。
• 政府和機構的資金：政府和機構為生物銀行建立和相關研究提供的資金通常是市場成長要素。資金將用於建立新的生物庫、擴大現有的生物庫以及改進和共用研究成果。在生物銀行工作中增加投資有助於在不斷研究的過程中產生先進的資源。
• 國際合作和資料共用：國際合作和資料共用正在刺激生物銀行市場的成長，因此處理更大和異質的資料變得更加容易。透過國際夥伴關係和網路，研究和知識交流能力將得到釋放。這些趨勢透過利用人力和生物庫資源來實現先前緩慢的研究，從而促進更好、更快的科學研究。

生物銀行市場面臨的挑戰是：

• 監管和道德問題：對於生物銀行，監管和道德合規不僅僅是市場力量。處理有關資料及其保護、相關人員同意和樣本處理的政策是一項非常耗時且會產生大量成本的工作。人們認知到，為了維護生物庫結構和營運框架的可信度和完整性，需要滿足道德考量和監管方面。
• 資料安全、保護和隱私：資料安全和隱私相關問題是生物銀行市場面臨的挑戰之一。保護高度個人化的健康和生物資料免遭洩露和未授權存取是一個問題。應採取網路安全實踐和法律措施來保護生質能資料免受損害，並確保公眾對生物庫及其業務的信任。
• 成本和基礎設施資源管理：建立和運作生物庫需要大量的資金投入，這可能具有挑戰性，尤其是對於較小的機構而言。所需的關鍵活動之一是在控制營運成本的同時獲得設備、資訊技術系統和人力資源的資金。成本控制和良好的資源管理實踐將是實現生物庫永續性的關鍵因素。

人們進行了​​進一步的研究來解釋得出這三個結論的具體原因，而生物銀行的理論基礎與許多應用科學社會學一樣已經發展起來。此外，包括但不限於技術革命、醫療保健行業個人化趨勢以及研究活動的成長等主要趨勢正在塑造生物銀行市場。解決這些促進因素和市場問題對於利用成長機會、增強研究潛力和克服生物銀行不斷變化的現實至關重要。

目錄

第1章執行摘要

第2章全球生物銀行市場：市場動態

• 簡介、背景和分類
• 供應鏈
• 產業驅動力與挑戰

第3章市場趨勢與預測分析（2019-2031）

• 宏觀經濟趨勢（2019-2024）及預測（2025-2031）
• 全球生物銀行市場趨勢（2019-2024）及預測（2025-2031）
• 全球生物銀行市場（按樣本類型）
  • 血液製品
  • 人體組織
  • 細胞株
  • 核酸
  • 體液
  • 人類排泄物
• 全球生物銀行市場（按產品和服務分類）
  • 裝置
  • 耗材
  • 服務
  • 軟體
• 全球生物銀行市場應用情況
  • 再生醫學
  • 生命科學研究
  • 臨床研究
• 全球生物銀行市場（按最終用途分類）
  • 製藥和生物技術公司、CRO（委外研發機構）
  • 學術研究所
  • 醫院

第4章區域市場趨勢與預測分析（2019-2031）

• 全球生物銀行市場（按地區）
• 北美生物銀行市場
• 歐洲生物銀行市場
• 亞太生物銀行市場
• 世界其他地區的生物銀行市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 全球生物銀行市場成長機會（依樣本類型）
  • 全球生物銀行市場（按產品和服務）的成長機會
  • 全球生物銀行市場的成長機會（按應用）
  • 全球生物銀行市場成長機會（依最終用途分類）
  • 全球生物銀行市場各區域成長機會
• 全球生物銀行市場的新興趨勢
• 戰略分析
  • 新產品開發
  • 全球生物銀行市場產能擴張
  • 全球生物銀行市場的企業合併
  • 認證和許可

第7章主要企業簡介

• Thermo Fisher Scientific
• PHC Holdings
• Becton
• Dickinson and Company
• QIAGEN NV
• Merck KGaA
• Avantor
• Cryoport
• Tecan Trading
• Azenta

The future of the global biobanking market looks promising with opportunities in the pharmaceutical & biotechnology company and CRO, academic & research institute, and hospital markets. The global biobanking market is expected to reach an estimated $6.8 billion by 2031 with a CAGR of 10.5% from 2025 to 2031. The major drivers for this market are the growing demand for genetic testing and precision medicine, the rising popularity of preserving newborns' cord blood stem cells, and the emergence of virtual biobanking software.

• Lucintel forecasts that, within the product & service category, equipment is expected to witness the highest growth over the forecast period.
• Within the application category regenerative medicine will remain the largest segment in the forecast period.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Biobanking Market

The biobanking market is changing currently due to the occurrence of new technologies, the rise of new research, and changing policies. New trends signal the movement of biobanks in terms of operations, use of information, and the role played in biomedical research. Such trends are important to those interested in taking advantage of the new, fast-developing, biobanking environment.

• Advanced Technologies Adoption: In order to improve data analysis and sample processing, biobanks are integrating sophisticated tools such as high-throughput sequencing, NGS, and artificial intelligence among others. These technologies maximize the effectiveness of biobank tasks making it possible to conduct in-depth research to reveal genetic and environmental risk factors of health and diseases including illness and stress.
• Growth of Personalized Medicine: One of the trends of the market is also the old reason for the increasing loud demand for bank data that focuses on the cure of a certain disease. New populations and new clinical collections are also expanding and biobanks are making possible research into developing individualized therapies and precision medicine. This trend helps to develop more accurate treatment options and improve the efficacy of medical treatment.
• Safeguarding of Data and its Confidentiality: As focus increases with regard to data privacy and security, biobanks have implemented deep-rooted systems for the protection of such data. Adhering to regulatory frameworks like GDPR and HIPAA has become a vision, and biobanks have stepped up into new horizons of data security including the safeguarding of health and biological data and embracing confidentiality.
• Building of Centrally Managed and Region-Wise Located Biobanks: This current trend has been noticed in numerous countries where they are establishing a common biobank or biobanks with regional offices to enhance population-based studies and other health-related research on a large pop
• Combination of Biobanks and Sharing of Data: More emphasis is made on the increase of the combination, and sharing of data, of the biobanks and research institutions. There are emerging partnerships and networks that make it possible for scientists to utilize many datasets, from which a wide array of research can be pursued, speeding up the pace of discovery. This trend increases the worth of biobank resources and allows for more extensive and effective research.

Building of Centrally Managed and Region-Wise Located Biobanks: This current trend has been noticed in numerous countries where they are establishing a common biobank or biobanks with regional offices to enhance population-based studies and other health-related research on a large pop

Recent Developments in the Biobanking Market

Recent transitions in the biobanking market are characterized by improvements in technological infrastructural and research parameters. These developmental milestones are likely to revolutionize biobanking as they will offer new perspectives on biological sample collection, handling, and analysis for research. Knowledge of these developments is important for the players in the market to understand where the market is headed and identify new possibilities.

• Establishment of Large-Scale Biobanks: The establishment of large-scale biobanks like the All of Us Research Program in the U.S. and the European and Asian national biobanks is worth noting. These biobanks focus on harvesting a wide and rich array of biological samples to conduct extensive research population projects and customized treatment. They deepen the level of detail that can be addressed and assist cutting-edge research in genetics and population health.
• Combining the Various Areas of Genomics with High Throughput Technologies: The combining of genomics and biobanks with high-throughput practices is contributing to the development of research effort expansion. The standard operating procedures include high-throughput sequencing and genomic analysis which now allows the in-depth evaluation of genetic materials and how they affect health and disease. This advancement leads to the generation of more targeted and effective research, which in turn allows for deeper insights and the eradication of even more diseases.
• Biobank Information Management System's Improvements: The recent trends in biobank data management systems are enhancing the effectiveness and speed with which biobanks are operating. Improved techniques of handling the biorepository data as well as bioinformatics software help in proper structuring, dissecting, and disseminating the Biobank data. These systems facilitate the incorporation of different types of data sets and streamline the workflows, hence improving the research output.
• More Attention is Given to Bioethics and Regulations: More attention is paid to the ethical and regulatory perspectives of biobanking. There are measures being put in place by biobanks to make sure that ethics and governance principles such as consent, confidentiality, and sample handling are being followed. This concern improves the efficiency and reliability of the operations of biobanks and promotes compliance with accepted standards.
• Increasing the Scale of Biobank Networks and Advances in Collaborations: The growing network and collaboration of the biobanks is an interesting trend as the biobanks are ready to collaborate for sharing resources and data. These collaborations allow making use of the greater and more varied datasets, benefiting from the synergies of research, and speeding the process of science. Embedding biobanks into global networks helps achieve more complete and significant research results.

Important recent advances in the biobanking field such as the creation of population biobanks, adoption of new information technologies, progress in information management, fulfillment of regulative requirements, and enlargements of networks are defining the evolution of the markets. These changes broaden the possibilities of conducting biobanking research, facilitate personalized medicine, and bring about progress in the healthcare industry as well as in biomedical research.

Strategic Growth Opportunities for Biobanking Market

In the biobanking market, there are several opportunities for growth in terms of the different applications available. By applying these opportunities, stakeholders will be able to enlarge their engagement in and ultimately influence, research and public health. This overview focuses on the biobanking framework growth dynamics and explains the key growth patterns along with prospects for wider applications defined by the domain extension of the market.

• Genomics Research: The trends of Geno-bank initiatives are increasing the demand for such a facility in the biobanking market. The biobanks provide a variety of populations and a large sample for genomic research. This application promotes research in the fields of genetic polymorphism, disease development, and treatments in disease management. Transferring the care of biobanks is looking to portions of the genomics research that will help grow those in other areas of precise and targeted medicine.
• Personalized Medicine: Personalized medicine is a bane for biobank opportunities and the growth of this segment cannot be overlooked. Biobanks are now positioned to facilitate research with actual biological specimens and detailed clinical history in support of individualized therapies and drug discovery. This application allows a more reliable diagnosis and a treatment that better targets the disease of the patient and further promotes the development of the personalized medicine field.
• Public Health Research: Biobanks are sources of samples essential for health-based research as well as for epidemiological studies including but not limited to the studies measuring disease occurrence, factors influencing the occurrence of diseases, and their control or prevention. Growth opportunities include enhancing crucial biobank resources for epidemiological and public health approaches. This enhances the ability to solve public health problems as well as design and implement effective health strategies and programs.
• Drug Development and Clinical Trials: Biobanks are the heart of any drug development or any clinical studies, as they offer biological investigation material for all possible needs. Joining such opportunities means cooperation with pharmaceutical and research companies for the needs of drug development and clinical studies. This application hastens the generation of potential drugs while improving the processes of drug development.
• Disease-Specific Biobanks: Developing disease-specific biobanks is another area for growth as constitutive biobanks such as the ones for cancer, cardiovascular diseases, or rare genetic diseases may be set up. These biobanks are beneficial for the investigation of a better understanding of the disease, its biomarkers, and its treatment options. This application promotes specific research work, however, further advances the needs of diagnosis and treatment of specific diseases.

Strategic biobanking miscues opportunities emerging in the biobanking market. Genomics research, personalization medicine, public health research, drug development, and disease-specific biobanks indicate areas of growing opportunity and impact. Taking advantage of these opportunities engages progress in research, improves individual healthcare, and solves significant public health problems.

Biobanking Market Driver and Challenges

The biobanking market is characterized by various drivers and challenges, including, but not limited to, technology, regulation, and economy. Stakeholders need to appreciate such drivers and challenges in order to maneuver into the market and harness such opportunities that are ever on the rise.

The factors responsible for driving the biobanking market include:

• Increasing Demand Text for Personalized Medicine: Resent emphasis on personalized medicine is a major booster in the biobanking market. The term "personalized treatment" clearly structures the concept of therapy requiring a great amount of biological and clinical data needed to provide such treatment. Biobanks assist this requirement with their provision of broad, comprehensive, and elaborate sample collections to investigate personalized medicine and enhance healthcare services.
• Inclusion of New Areas in Research Initiatives: The demand for biobank resources is increasing because the scope of research initiatives including genomics, epidemiology, and drug development is broadening. Understanding the growth of these research efforts, there is therefore an increasing demand for more biological specimens that are specific as well as easily available and accessible. Biobanks have embarked on the process of increasing the number of biological specimens that they have and the scope at which they serve different research purposes to make meaningful scientific contributions.
• Government and Institutional Funding: Often, funding provided by the government and the institutions for building and biobanking and research related to it constitutes the core growing factor of the market. Funding helps to set up new biobanks and extend existing ones, to improve research work and to help share it. Increased investment in biobanking initiatives helps to create advanced resources during this period of constant research.
• International Collaboration and Data Sharing: International collaboration and data sharing are stimulating the growth of the biobanking market and due to this reason, it is easier to work with larger and more heterogeneous sets of data. Research and knowledge exchange capabilities are opened up through international partnerships and networks. This trend fosters better and faster science as research that would have taken longer to conduct is made possible by the availability of talent and biobank resources.

Challenges in the biobanking market are:

• Regulation and Ethical Issues: Regulatory and ethical compliance is more than one of the market forces for biobanking. Dealing with policies regarding the data and its protection, consent of parties and sample handling can be a very slow undertaking quite expensive. It is recognized that ethical considerations and regulatory aspects should be met to retain the credibility and integrity of the biobank structure and operational framework.
• Data Security, Protection, and Privacy: Data security and privacy-related issues are among the biobanking market challenges. Safeguarding very personal health-biological data from leakage and abusive access is an issue. Cybersecurity practices and legal measures should be performed to protect biomass data from harm and ensure public confidence in biobanks and their practices
• Costs and Infrastructure Resource management: Setting up and running biobanks will involve significant financial investments which particularly for small institutions can prove a challenge. One of the major activities that will be required is sourcing funds for equipment, information technology systems as well as human resources while controlling operational costs. Cost containment and proper resource management practices will be critical factors in the achievement of sustainability of the biobank.

Further studies have been done to illustrate specific reasons why these three conclusions should be achieved, the theoretical base of biobanking has been developed as much of the applied sociology of science. Further, the major forces including but not limited to the technological revolution, the personalization trend in the healthcare industry, and the growth in research activity take the shape of the biobanking market. Tackling these drivers and Market problems is essential for utilizing growth opportunities, increasing the research possibilities, and conquering the changing reality of biobanking.

List of Biobanking Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies biobanking companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the biobanking companies profiled in this report include-

• Thermo Fisher Scientific
• PHC Holdings
• Becton
• Dickinson and Company
• QIAGEN N.V.
• Merck KGaA
• Avantor
• Cryoport
• Tecan Trading
• Azenta

Biobanking by Segment

The study includes a forecast for the global biobanking market by sample type, product & service, application, end use, and region.

Biobanking Market by Sample Type [Analysis by Value from 2019 to 2031]:

• Blood Products
• Human Tissues
• Cell Lines
• Nucleic Acids
• Biological Fluids
• Human Waste Products

Biobanking Market by Product & Service [Analysis by Value from 2019 to 2031]:

• Equipment
• Consumables
• Services
• Software

Biobanking Market by Application [Analysis by Value from 2019 to 2031]:

• Regenerative Medicine
• Life Science Research
• Clinical Research

Biobanking Market by End Use [Analysis by Value from 2019 to 2031]:

• Pharmaceutical & Biotechnology Companies and CROs
• Academic & Research Institutes
• Hospitals

Biobanking Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Biobanking Market

The biobanking market has evolved positively due to technological advancements, increased research demands, and a focus on personalized medicine. Biobanks play a crucial role in medical research and therapy development by collecting and preserving biological specimens. Insights into the biobanking landscape in the USA, China, Germany, India, and Japan illustrate the scale and direction of the market amid changing policies and technologies.

• United States: In the U.S., biobanking has made significant strides through the integration of high-throughput gene sequencing and bioinformatics. Initiatives like the All of Us Research Program focus on broad data collection to improve services. Increased funding and public-private partnerships are enhancing biobank capabilities and supporting advances in disease therapeutics and research.
• China: China has heavily invested in its biobanking network, driven by government policies aimed at enhancing biotechnological capabilities and healthcare systems. This includes creating large-scale biobanks and forming collaborations with global organizations. China is also working to advance its legislative policies to ensure the ethical use and security of biological materials and data.
• Germany: Germany's biobank growth is supported by robust legislation and high standards for handling patient data and bioethics. The German Biobank Node promotes European data collection and sharing for scientific purposes. Recent efforts focus on integrating biobank data with clinical information to enhance research and precision medicine initiatives.
• India: India's biobanking segment is developing due to increasing research activities and government support for biomedical initiatives. New biobanks and expansions of existing ones, such as the Indian Genome Variation Consortium, are emerging. The country aims to strengthen infrastructure and data support for genomics, personalized medicine, and public health research through international partnerships.
• Japan: Japan's biobanking market is evolving through technological advancements and personalized medicine strategies. Recent developments include large-scale biobanks and partnerships with international counterparts. Japan is also working to integrate biobank data with electronic health records to improve research and clinical care while enhancing regulatory and ethical frameworks.

Features of the Global Biobanking Market

Market Size Estimates: Biobanking market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Biobanking market size by various segments, such as by product & service, sample type , application, end use industry, and region in terms of ($B).

Regional Analysis: Biobanking market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product & service, sample types , applications, end use industries, and regions for the biobanking market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the biobanking market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the biobanking market by sample type (blood products, human tissues, cell lines, nucleic acids, biological fluids, and human waste products), product & service (equipment, consumables, services, and software), application (regenerative medicine, life science research, and clinical research), end use (pharmaceutical & biotechnology companies and CROs, academic & research institutes, and hospitals), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Biobanking Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Biobanking Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Biobanking Market by Sample Type
  • 3.3.1: Blood Products
  • 3.3.2: Human Tissues
  • 3.3.3: Cell Lines
  • 3.3.4: Nucleic Acids
  • 3.3.5: Biological Fluids
  • 3.3.6: Human Waste Products
• 3.4: Global Biobanking Market by Product & Service
  • 3.4.1: Equipment
  • 3.4.2: Consumables
  • 3.4.3: Services
  • 3.4.4: Software
• 3.5: Global Biobanking Market by Application
  • 3.5.1: Regenerative Medicine
  • 3.5.2: Life Science Research
  • 3.5.3: Clinical Research
• 3.6: Global Biobanking Market by End Use
  • 3.6.1: Pharmaceutical & Biotechnology Companies and CROs
  • 3.6.2: Academic & Research Institutes
  • 3.6.3: Hospitals

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Biobanking Market by Region
• 4.2: North American Biobanking Market
  • 4.2.1: North American Biobanking Market by Product & Service: Equipment, Consumables, Services, and Software
  • 4.2.2: North American Biobanking Market by End Use: Pharmaceutical & Biotechnology Companies and CROs, Academic & Research Institutes, and Hospitals
• 4.3: European Biobanking Market
  • 4.3.1: European Biobanking Market by Product & Service: Equipment, Consumables, Services, and Software
  • 4.3.2: European Biobanking Market by End Use: Pharmaceutical & Biotechnology Companies and CROs, Academic & Research Institutes, and Hospitals
• 4.4: APAC Biobanking Market
  • 4.4.1: APAC Biobanking Market by Product & Service: Equipment, Consumables, Services, and Software
  • 4.4.2: APAC Biobanking Market by End Use: Pharmaceutical & Biotechnology Companies and CROs, Academic & Research Institutes, and Hospitals
• 4.5: ROW Biobanking Market
  • 4.5.1: ROW Biobanking Market by Product & Service: Equipment, Consumables, Services, and Software
  • 4.5.2: ROW Biobanking Market by End Use: Pharmaceutical & Biotechnology Companies and CROs, Academic & Research Institutes, and Hospitals

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Biobanking Market by Sample Type
  • 6.1.2: Growth Opportunities for the Global Biobanking Market by Product & Service
  • 6.1.3: Growth Opportunities for the Global Biobanking Market by Application
  • 6.1.4: Growth Opportunities for the Global Biobanking Market by End Use
  • 6.1.5: Growth Opportunities for the Global Biobanking Market by Region
• 6.2: Emerging Trends in the Global Biobanking Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Biobanking Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biobanking Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Thermo Fisher Scientific
• 7.2: PHC Holdings
• 7.3: Becton
• 7.4: Dickinson and Company
• 7.5: QIAGEN N.V.
• 7.6: Merck KGaA
• 7.7: Avantor
• 7.8: Cryoport
• 7.9: Tecan Trading
• 7.10: Azenta